Progesterone receptor
From Proteopedia
(Difference between revisions)
(New page: <StructureSection load='1p6o' size='350' side='right' caption='Structure of yeast cytosine deaminase complex with pyrimidine-based inhibitor, acetate, Ca+2 (green) and Zn+2 (grey) ions (PD...) |
|||
| Line 1: | Line 1: | ||
| - | <StructureSection load=' | + | <StructureSection load='2w8y' size='350' side='right' caption='Structure of human progesterone receptor ligand-binding domain complex with RU486 (PDB entry [[2w8y]])' scene=''> |
| - | + | ||
| - | + | ||
== Function == | == Function == | ||
| - | + | '''Progesterone receptor''' (PR) binds to DNA and inhibits transcription. The inhibition terminates when progesterone binds to PR. The ovarian steroid progesterone which is essential for breast development and reproductive behavior, is mediated by PR<ref>PMID:19072517</ref>. | |
== Relevance == | == Relevance == | ||
| + | |||
| + | The response to hormone therapy in breast cancer correlates with PR. PR absence in breast tumor cells predicts resistance to hormone therapy <ref>PMID:16234531</ref>. | ||
== Structural highlights == | == Structural highlights == | ||
| - | + | The structure of the complex of the ligand-binding domain of PR with RU486 - an abortion-inducing drug - shows the ligand bound at a similar location to other agonists or partial agonists with a flexible loop of PR being a possible entry route to the binding site and several PR-RU486 interactions<ref>PMID:19372222</ref>. | |
</StructureSection> | </StructureSection> | ||
== 3D Structures of progesterone receptor == | == 3D Structures of progesterone receptor == | ||
Revision as of 11:20, 15 February 2018
| |||||||||||
3D Structures of progesterone receptor
Updated on 15-February-2018
References
- ↑ Lange CA, Yee D. Progesterone and breast cancer. Womens Health (Lond). 2008 Mar;4(2):151-62. doi: 10.2217/17455057.4.2.151. PMID:19072517 doi:http://dx.doi.org/10.2217/17455057.4.2.151
- ↑ Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct 20;23(30):7721-35. doi: 10.1200/JCO.2005.09.004. PMID:16234531 doi:http://dx.doi.org/10.1200/JCO.2005.09.004
- ↑ Raaijmakers HC, Versteegh JE, Uitdehaag JC. The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. J Biol Chem. 2009 Jul 17;284(29):19572-9. Epub 2009 Apr 16. PMID:19372222 doi:http://dx.doi.org/10.1074/jbc.M109.007872
